A not-for-profit organisation dedicated to encouraging life sciences R&D has launched a new tool to help companies in the sector design better apps and digital tools.
AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late-stage trial success.